Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.44 |
| ▸ | CA12 | O43570 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA4 | P22748 | 4/20 | 0.44 |
| ▸ | CA9 | Q16790 | 4/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | KDM5C | P41229 | 3/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.38 |
| ▸ | KDM6B | O15054 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | EPOR | P19235 | 1/20 | 0.37 |
| ▸ | ECE1 | P42892 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23157565 | 1.00 | CA2 (0.44) | CA2CA12CA1CA4CA9 | |
| SCHEMBL23157519 | 1.00 | CA2 (0.44) | CA2CA12CA1CA4CA9 | |
| SCHEMBL23157585 | 1.00 | CA2 (0.44) | CA2CA12CA1CA4CA9 | |
| SCHEMBL2323385 | 0.98 | CA2 (0.42) | CA2CA12CA1CA4CA9 | |
| SCHEMBL19172671 | 0.93 | CA2 (0.49) | CA2CA12CA1CA4CA9 | |
| SCHEMBL23158185 | 0.91 | CA2 (0.40) | CA2CA12CA1CA4CA9 | |
| SCHEMBL17447162 | 0.91 | CA2 (0.40) | CA2CA12CA1CA4CA9 | |
| SCHEMBL15728323 | 0.91 | CA12 (0.46) | CA2CA12CA1CA4CA9 | |
| SCHEMBL29896372 | 0.91 | CA12 (0.46) | CA2CA12CA1CA4CA9 | |
| SCHEMBL23157878 | 0.90 | TSHR (0.43) | CA2CA12CA1CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3453711-B1 | LLP2A- BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | UNIV CALIFORNIA (US) | 2021-08-18 | — | — | EP | claimed |
| US-20200369723-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-26 | — | — | US | claimed |
| EP-3453711-A1 | LLP2A- BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | The Regents of the University of California (US) | 2019-03-13 | — | — | EP | claimed |
| EP-2753626-B1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | UNIV CALIFORNIA (US) | 2018-08-08 | — | — | EP | claimed |
| US-20170174722-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-06-22 | — | — | US | claimed |
| US-9561256-B2 | LLP2A-bisphosphonate conjugates for osteoporosis treatment | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-07 | — | — | US | claimed |
| US-20160074461-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-03-17 | — | — | US | claimed |
| US-9119884-B2 | LLP2A-bisphosphonate conjugates for osteoporosis treatment | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-09-01 | — | — | US | claimed |
| US-20140056855-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-27 | — | — | US | claimed |
| WO-2013032527-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-07 | — | — | WO | claimed |
| WO-2012031228-A2 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-08 | — | — | WO | claimed |
| US-12559529-B2 | NPY2 receptor agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2026-02-24 | — | — | US | disclosed |
| US-20260015399-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2026-01-15 | — | — | US | disclosed |
| US-12391737-B2 | Soluble NPY2 receptor agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-08-19 | — | — | US | disclosed |
| CN-112672747-B | Peptides for activating cell signaling in osteoprogenitor cells | 加利福尼亚大学董事会 | 2025-02-18 | — | — | CN | disclosed |
| WO-2009115469-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | WO | disclosed |
| US-7576175-B2 | Amino acid terminated diphenylurea derivatives; display high binding affinity, specificity, and stability; use in treating cancer, inflammatory diseases, and autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-08-18 | — | — | US | disclosed |
| WO-2009022006-A1 | INSULINS WITH AN ACYL MOIETY COMPRISING REPEATING UNITS OF ALKYLENE GLYCOL CONTAINING AMINO ACIDS | NOVO NORDISK A/S (DK) | 2009-02-19 | — | — | WO | disclosed |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | disclosed |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | ITGA4, ITGB4, ITGA1 | CA2 4144/4885CA12 2713/4885CA1 2626/4885 |
| US-20170174722-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | LCP1, BST2, ITGA2B | CA2 3873/4885CA12 4199/4885CA1 4637/4885 |
| US-20200369723-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | LCP1, BST2, ITGA2B | CA2 3873/4885CA12 4199/4885CA1 4637/4885 |
| US-20140056855-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | LCP1, BST2, ITGA2B | CA2 3873/4885CA12 4199/4885CA1 4637/4885 |
| US-20160074461-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | LCP1, BST2, ITGA2B | CA2 3873/4885CA12 4199/4885CA1 4637/4885 |
| US-12391737-B2 | Soluble NPY2 receptor agonists | NPY2R, NPY1R, NPY5R | CA2 1305/4885CA12 2621/4885CA1 3171/4885 |
| US-20260015399-A1 | SOLUBLE NPY2 RECEPTOR AGONISTS | NPY1R, NPY2R, NPY5R | CA2 700/4885CA12 1835/4885CA1 1432/4885 |
| US-12559529-B2 | NPY2 receptor agonists | NPY2R, NPY5R, NPY1R | CA2 1625/4885CA12 2728/4885CA1 4390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.